tbuckley/cabot-search huggingface dataset:
Identification of a Novel Fusion Gene,<i>IRF2BP2-RARA</i>, in Acute Promyelocytic Leukemia
Authors: C. Cameron Yin, Nitin Jain, Meenakshi Mehrotra, Jianhua Zhagn, Alexei Protopopov, Zhuang Zuo, Naveen Pemmaraju, Courtney DiNardo, Cheryl Hirsch-Ginsberg, Sa A. Wang, L. Jeffrey Medeiros, Lynda Chin, Keyur P. Patel, Farhad Ravandi, Andrew Futreal, Carlos E. Bueso-Ramos
Journal: Journal of the National Comprehensive Cancer Network (2015)

Acute promyelocytic leukemia (APL) is characterized by the fusion of retinoic acid receptor alpha (RARA) with promyelocytic leukemia (PML) or, rarely, other gene partners. This report presents a patient with APL with a novel fusion between RARA and the interferon regulatory factor 2 binding protein 2 (IRF2BP2) genes. A bone marrow examination in a 19-year-old woman who presented with ecchymoses and epistaxis showed morphologic and immunophenotypic features consistent with APL. PML oncogenic domain antibody was positive. Results of fluorescence in situ hybridization, conventional cytogenetics, reverse transcription–polymerase chain reaction (RT-PCR), and oligonucleotide microarray for PML-RARA and common APL variant translocations were negative. Next-generation RNA-sequencing analysis followed by RT-PCR and direct sequencing revealed distinct breakpoints within IRF2BP2 exon 2 and RARA intron 2. The patient received all-trans retinoic acid, arsenic, and gemtuzumab ozogamicin, and achieved complete remission. However, the disease relapsed 10 months later, 2 months after consolidation therapy. This is the first report showing involvement of IRF2BP2 in APL, and it expands the list of novel RARA partners identified in APL.
How often should we go to the dentist?
Authors: E. J Kay
Journal: BMJ (1999)

The 1993 United Kingdom Child Dental Health Survey showed that children who only attended dentists when having problems had more decayed and filled teeth than children who attended when asymptomatic.1 The so called “regular” attenders tended to have fewer teeth extracted. A similar survey of adults also showed that those who had check ups had almost half as many teeth missing as those who visited the dentist only when they had a problem.2 At first glance therefore the evidence suggests that individuals who go the dentist to seek treatment before symptoms arise actually do suffer fewer sequelae from the progression of dental disease. The picture is not, however, that simple.

Oral ill health shows a social class gradient just as every other chronic lifestyle related disease does.1–3 The most affluent and socially advantaged individuals suffer low levels of dental disease, and those in the poorest and most disadvantaged groups have the highest disease rates. Similarly, those in higher socioeconomic groups are more likely to register with a dentist and are more likely to attend for check ups when …
Progress Toward Polio Eradication — Worldwide, 2015–2016
Authors: Michelle Morales, Rudolf H. Tangermann, Steven G.F. Wassilak
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

In 1988, the World Health Assembly resolved to eradicate poliomyelitis. Wild poliovirus (WPV) transmission persists in only two countries (Afghanistan and Pakistan) after the removal of Nigeria from the list of countries with endemic polio in September 2015.* Indigenous WPV type 2 has not been detected since 1999 and was declared eradicated by the Global Commission for the Certification of Poliomyelitis Eradication in September 2015.(†) Since November 2012, when the last case of WPV type 3 was detected in Nigeria, WPV type 1 has been the sole circulating type of WPV (1). This report summarizes global progress toward polio eradication during 2015-2016 and updates previous reports (2). In 2015, 74 WPV cases were reported in two countries (Afghanistan and Pakistan), a decrease of 79% from the 359 WPV cases reported in 2014 in nine countries; 12 WPV cases have been reported in 2016 (to date), compared with 23 during the same period in 2015 (3). Paralytic polio caused by circulating vaccine-derived poliovirus (cVDPV) remains a risk in areas with low oral poliovirus vaccine (OPV) coverage. Seven countries, including Pakistan, reported 32 cVDPV cases in 2015 (4). In four of these countries, ≥6 months have passed since the most recent case or isolate. One country (Laos) with VDPV transmission in 2015 has reported three additional cVDPV cases in 2016 to date. Encouraging progress toward polio eradication has been made over the last year; however, interruption of WPV transmission will require focus on reaching and vaccinating every missed child through high quality supplementary immunization activities (SIAs) and cross-border coordination between Afghanistan and Pakistan (5,6).
The Nature and Treatment of Plummer--Vinson Dysphagia
Authors: J. A. W. Bingham, J. S. Logan
Journal: BMJ (1953)

This syndrome of dysphagia of upper oesophageal type associated with present or past anaemia is relatively common in the North of Ireland.Treatment by dilata- tion is very satisfactory, but the condition is unfor- tunately often misdiagnosed as hysteria or "nervous swallow."Indeed, Vinson in 1922 put forward the view that the dysphagia was hysterical.We have been impressed by the diagnostic difficulty the condition evidently offers and by the consequent prolonged physical and social distress the patient suffers.That the condition is due to an organic stricture and that relief may be obtained by dilatation have been pointed out by McGibbon (1935), but these observations have not become widely known.This account is based on 16 cases observed in the last five years.Details of these cases are given in the Table. Clinical FeaturesThe clinical features have often been described, among others by McKenzie (1918), Brown Kelly (1919, 1927), Paterson (1919), and Munro Cameron (1928, 1929).The onset is insidious and the course lasts many years.There is no tendency to spontaneous cure.The social class and
Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition
Authors: Ana Collazo-Lorduy, Mireia Castillo-Martin, Li Wang, Vaibhav Patel, Gopa Iyer, Emmet Jordan, Hikmat Al-Ahmadie, Issa Leonard, William K. Oh, Jun Zhu, Russell B. McBride, Carlos Cordon-Cardo, David B. Solit, John P. Sfakianos, Matthew D. Galsky
Journal: European Urology (2016)
Reports Warn of Primary Care Shortages
Authors: Bridget M Kuehn
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4114: Quantitative Trait Loci Influencing Low-Density Lipoprotein Particle Size in African Americans
Authors: Iftikhar J Kullo, Keyue Ding, Eric Boerwinkle, Stephen T Turner, Mariza de Andrade
Journal: Circulation (2006)

Background: Genomic regions that influence LDL particle size in African-Americans are not known. We performed linkage analyses to identify genomic regions that influence LDL particle size and also ...
Abstract 9485: Cardiac G Protein-Coupled Receptor Kinase 2 Knockdown Decreases Ischemia/Reperfusion-Induced Injury and Improves Cardiac Function through Anti-Apoptotic Mechanisms
Authors: Qian Fan, Mai Chen, Xiying Shang, Michele Ciccarelli, Z. Maggie Huang, Philip Raake, J K Chuprun, Gerald W Dorn Ii, Walter J Koch, Erhe Gao
Journal: Circulation (2010)

Background: Studies from our lab have shown that decreasing myocardial G protein-coupled receptor kinase 2 (GRK2) expression or preventing GRK2 activation with an inhibitory peptide (βARKct) can prevent or rescue heart failure after myocardial infarction. In this study we investigated the acute cardiac effects associated with lowered myocyte GRK2 expression in a mouse model of ischemia/reperfusion (I/R) injury. Methods: Cardiomyocyte-specific GRK2 knockout (KO) mice were used with either GRK2 deleted at birth or inducible GRK2 deletion along with appropriate control mice that included GRK2 floxed mice and αMHC-Cre and MerCreMer mice. All mice were subjected to sham or 30 min myocardial ischemia via coronary artery ligation followed by 24 hrs reperfusion. Cardiac function, infarct size, tissue apoptosis (TUNEL and Caspase activity) and changes in the activation state of various signaling molecules (Akt, GSK3β, ERK, p38, JNK and cytochrome C) were analyzed. Results: Echo and hemodynamic measurements showed ...
Index of Suspicion
Authors: Uptal D. Patel, Harry Hollander, Sanjay Saint
Journal: New England Journal of Medicine (2004)

A 26-year-old woman with end-stage renal disease from primary membranoproliferative glomerulonephritis who had received her second cadaveric renal transplant 11 months previously presented with a 2-week history of intermittent fever, with temperatures as high as 39°C.
Quality of Life of Adults With Congenital Heart Disease in 15 Countries
Authors: Silke Apers, Adrienne H. Kovacs, Koen Luyckx, Corina Thomet, Werner Budts, Junko Enomoto, Maayke A. Sluman, Jou-Kou Wang, Jamie L. Jackson, Paul Khairy, Stephen C. Cook, Shanthi Chidambarathanu, Luis Alday, Katrine Eriksen, Mikael Dellborg, Malin Berghammer, Eva Mattsson, Andrew S. Mackie, Samuel Menahem, Maryanne Caruana, Gruschen Veldtman, Alexandra Soufi, Anitra W. Romfh, Kamila White, Edward Callus, Shelby Kutty, Steffen Fieuws, Philip Moons
Journal: Journal of the American College of Cardiology (2016)
Thomas Bowdler (1754–1825)
Authors: Robert W. Buck
Journal: New England Journal of Medicine (1958)

SWINBURNE (whose own Poems and Ballads many an intelligent and imaginative Victorian maiden dared not read) has stated, "No man ever did better service to Shakespeare than the man who made it possible to put him into the hands of intelligent and imaginative children." He was speaking of Dr. Thomas Bowdler (M.D., Edinburgh, 1776), who also expurgated Gibbon's History of the Decline and Fall of the Roman Empire and selections from the Old Testament for the use of children. The word bowdlerize, meaning "to expurgate by omitting or modifying parts considered indelicate or offensive," has become a part of . . .
Cancer related fatigue: Central or peripheral?
Authors: M. P. Davis, V. Ranganthan, D. Walsh, V. Siemionow, G. Yue, J. Kirkova, T. Yavuzsen, S. B. LeGrand, R. L. Lagman
Journal: Journal of Clinical Oncology (2005)

8048 Introduction: Cancer related fatigue (CRF) occurs in more than 70% of cancer patients and is a major factor in determining quality of life. Several fatigue specific symptom assessment tools have been developed but the pathophysiology and site of origin of CRF is not known. Fatigue may originate from CNS and/or from the peripheral neuromuscular system. We therefore studied the EEG and EMG signals of hand muscles and brachioradialis during a sustained contraction in advanced cancer patients. Method: Patients with advanced solid tumors, < 10% weight loss and age-, gender-, and Body Mass Index (BMI)-matched healthy controls were studied. Cancer patients and healthy controls completed a Brief Fatigue Inventory (BFI). Cancer patients were not on antidepressants, had Hgb > 10% and were at least 4 weeks from last chemotherapy or radiation treatment. The relative decline in handgrip and elbow flexion force was measured pre and post fatigue. Results: The relative decline in hand grip force, elbow flexion force, and brachioradialis m. M-wave pre and post fatigue were not significantly different. However, twitch force and fatigue demonstrated greater muscle reserve in cancer patients. Discussion: The relative decline in muscle force at the onset of fatigue was similar for cancer and normal individuals. Overall muscle strength was reduced and the time to fatigue onset is shorted with CRF. Electroencephalographic (EEG) correlates are being analyzed. CRF was associated with reduced recruitment of motor units at the onset of fatigue. This suggests that the site of origin is central. Conclusion: CRF appears to be of central origin. No significant financial relationships to disclose.
A third of US antibiotic prescriptions are inappropriate, finds CDC study
Authors: Owen Dyer
Journal: BMJ (2016)

Nearly a third of all antibiotic prescriptions written in the United States are given to patients who will not benefit or do not meet the clinical criteria for treatment with antibacterials, concludes a study published in JAMA , the journal of the American Medical Association.1

Researchers from the US Centers for Disease Control and the non-profit, non-governmental organization Pew Charitable Trusts looked at data from more than 184 000 visits to doctor’s offices, hospital clinics, and emergency departments, drawing from the 2010-2011 National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey.

Of these visits, 12.6% resulted in antibiotic prescriptions. For every …
Long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) activity and efficacy in high-risk relapsed/refractory neuroblastoma patients.
Authors: Holger N. Lode, Dominique Valteau-Couanet, Alberto Garaventa, Juliet Gray, Victoria Castel, Isaac Yaniv, Nikolai Siebert, Christian Jensen, Stefanie Endres, Lena Pill, Christin Eger, Diana Seidel, Madlen Juettner, Silke Kietz, Karoline Ehlert, Evelyne Janzek, Hans Loibner, Ina Mueller, Ruth L Ladenstein
Journal: Journal of Clinical Oncology (2015)

TPS10080 Background: Long-term infusion (LTI) of anti-GD2 antibody ch14.18/CHO may improve outcome in patients (pts) with high risk relapsed/refractory neuroblastoma (NB). Methods: 97 pts received 6x106 IU/m2 sc IL2 (d1-5; 8-12), LTI of 100 mg/m2 ch14.18/CHO (d8-17) and 160 mg/m2 oral 13-cis-RA (d19-32) in an ongoing SIOPEN Phase II study (APN311-202) (NCT01701479) (44 pts) and a closed single center program (53 pts) (APN311-303). Response assessments followed INRG criteria. Fcγ-receptor polymorphisms FCGR2A (H131R), -3A (V158F) and -3B (NA1/NA2) were determined. Results: A decreasing degree of morphine usage and low pain scores were observed. Clinical overall responses were 30% (APN311-303) and 31% (APN311-202). The survival update of the APN311-303 cohort revealed a 1-y & 4-y OS of 94.2±3.2% & 60.9±9.0% (median FU 2.9y [0.7-5.2y]) and a 1-y & 4-y PFS of 54.4±6.9% & 32.3% ±6.9% (median FU 2.8y [0.7 - 4.9y]). Median TTP was 571d (95% CI: 232.7d). The comparator is the reported historical gold standard with 1-y & 4-y PFS of 19±2% & 8±3% and OS of 56±3% & 14±4% and a median TTP of 63 d (95% CI: 56.8d). NB pts with high affinity FCGR alleles and an increase in ADCC (cut off 15%) are associated with longer PFS and OS rates (p < 0.03; p < 0.005), which supports NK-cell mediated ADCC as the mechanism of action. Parameters of immune modulation (CDC, and WBT) and pharmacokinetics (PK) of ch14.18/CHO were comparable between APN311-202 and -303 cohorts. PK of ch14.18/CHO was analyzed in cycle 1: Cmax= 12.2±0.4μg/ml, t½= 8.4±1.1 d, AUC = 145.3± 5.8 μg*d/ml, Vd = 9.3±0.5L/m2. A pro-inflammatory cytokine response (IL-2, IL-6, IL-8, IFNγ) translated into the expansion of effector NK- (3x) and T-cells (2x). We observed HACA in 17/97 pts (17.5%) of which only 9/97 (9.3%) were neutralizing with respect to the inhibition of CDC and WBT activity. In HACA negative patients, levels of ch14.18/CHO and functional parameters (CDC, WBT) analyzed before subsequent treatment cycles indicate persistent anti-NB activity for the entire treatment period. Conclusion: LTI of ch14.18/CHO is active and effective in high-risk relapsed/refractory NB. Clinical trial information: NCT01701479.
Thymidine Kinase (TK) Gene-Transduced Human Lymphocytes Can Be Highly Purified, Remain Fully Functional, and Are Killed Efficiently With Ganciclovir
Authors: N.C. Munshi, R. Govindarajan, R. Drake, L.M. Ding, R. Iyer, R. Saylors, J. Kornbluth, S. Marcus, Y. Chiang, D. Ennist, L. Kwak, C. Reynolds, G. Tricot, B. Barlogie
Journal: Blood (1997)
Difference of Neoadjuvant Treatment for Esophageal Cancer Between Japan and Western Countries
Authors: Yoshitaka Honma, Ken Kato, Hirokazu Syoji, Natsuko Okita, Atsuo Takashima, Satoru Iwasa, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada
Journal: Annals of Oncology (2014)
Drug and psychotherapy interactions in depression
Authors: Covi L, Lipman Rs, Alarcon Rd, Smith Vk
Journal: American Journal of Psychiatry (1976)

The authors conducted a series of multiple regression analyses of data from depressed patients. They found that 8 factors consistently predicted treatment response: a lower initial level of distress, imipramine treatment, a positive attitude toward group psychotherapy, and a good employment history predicted lower posttreatment distress levels; estrogen maintenance treatment was related to better response to diazepam, and a low level of intelligence predicted better response to both diazepam and imipramine; and a low initial level of interpersonal sensitivity and a significant other's having an unfavorable attitude toward psychiatric treatment were associated with better response to group psychotherapy.Multiple regression analyses of experimental data from emotionally depressed patients were conducted to determine factors bearing on the prediction of response to 6 types of treatment of depression. The following 8 factors were found to consistently predict favorable response to treatment: 1) lower initial level of distress, 2) treatment with imipramine, 3) a good employment history, 4) a positive attitude toward group psychotherapy, 5) estrogen replacement therapy enhanced the response to diazepam, 6) a low level of intelligence was predictive of a better response to diazepam and imipramine, 7) a low initial level of interpersonal intersensitivity, and 8) an unfavorable attitude toward psychiatric treatment was associated with a better response to group psychotherapy.
Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study.
Authors: Ana Oaknin, Anne Floquet, Christophe Le Tourneau, Isabelle Laure Ray-Coquard, Florence Joly, Manuel Hidalgo, Alexandra Leary, Oliver Krieter, Angelika Lahr, Simona Rossomanno, Katharina Lechner, Tapan Nayak, Christophe Boetsch, Grozdana Rasuo, Anthony Morel, Ignace Vergote
Journal: Journal of Clinical Oncology (2015)

5549 Background: Vanucizumab is a bi-specific human IgG1 antibody, simultaneously blocking the complementary roles of Ang-2 and VEGF-A induced tumor angiogenesis. Both, VEGF-A and Ang-2 inhibitors are known to be clinically active in ovarian cancer. Hence, co-targeting of both ligands in a bi-specific manner represents an encouraging approach to improve treatment outcomes. Methods: Eligiblepatients (pts) had platinum (Pt)- resistant/refractory epithelial OC (measurable by RECIST 1.1). Pts with history of bowel obstruction, > 2 prior lines of systemic chemotherapy, or previous treatments with agents targeting Ang/Tie2 receptor axis were ineligible. Pts were treated with vanucizumab (RP2D) at 30 mg/kg IV Q2W until disease progression or unacceptable toxicity. Primary endpoint was objective response rate (ORR) per RECIST 1.1, with tumor re-assessments every 8 weeks (wks). Results: 41 pts (40 Pt- resistant/ 1 Pt- refractory) with median age of 60 years (range 30-77) were enrolled. 13 (32%) pts were pre-treated with bevacizumab (BEV). All pts had at least 1 tumor re-assessment. At this point in time, twelve (29%) pts achieved partial response (6 confirmed PR/6 unconfirmed PR) including two pre-treated with BEV. Interestingly, a delayed response was observed in 7/12 PRs, following 16 wks (6 pts) or 32 wks (1 pt) of treatment. 22 (54%) pts experienced disease stabilization and 7 (17%) pts progressed. The most frequent adverse events (AE) of any grade (G) were hypertension (53%), asthenia (39%), constipation (34%), abdominal pain (32%), peripheral (24%)/lymphedema (19%), vomiting (24%) and diarrhea (19%). Most common AEs ≥ G3 were hypertension (10/24%), pyelonephritis (3/7%), GI-perforation, peritonitis, intestinal obstruction, pulmonary embolism and dyspnea (2/5%). One AE of peritonitis had a fatal outcome 3 months after onset. Conclusions: In this study, vanucizumab Q2W had an acceptable safety profile while demonstrating encouraging anti-tumor activity in pts with Pt-resistant, recurrent OC that seems to exceed reported results for single VEGF-A inhibition in this setting. Clinical trial information: NCT01688206.
Intestinal Glucose-6-Phosphatase in Control Subjects and Relatives of Patient with Glycogen Storage Disease
Authors: H E WILLIAMS, P L JOHNSON, L F FENSTER, L LASTER, J B FIELD
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Locally Recurrent Endometrial Cancer: A Case Report
Authors: Srinivas K. Tantravahi,, Theresa L. Werner
Journal: Journal of the National Comprehensive Cancer Network (2012)

Endometrial cancer is the most common malignancy of the female genital tract. It is typically a disease of postmenopausal women and often presents with postmenopausal vaginal bleeding. In 75% of cases, it is diagnosed at an early stage and is associated with better overall survival rates than many malignancies. The appropriate staging surgery for patients diagnosed with endometrial cancer is a total hysterectomy and bilateral salpingo-oophorectomy with pelvic and para-aortic lymphadenectomy. Adjuvant radiation therapy in early-stage disease is associated with decreased rates of locoregional recurrences but does not improve overall survival. The role of chemotherapy is not well established for early-stage disease. Treatment recommendations for locoregional recurrence of endometrial cancer after hysterectomy are poorly defined and include tumor-directed radiation therapy, and/or chemotherapy, and/or surgical resection. Because the current guidelines are not specific, they are confusing to clinicians. To illustrate this, this report presents a patient who was diagnosed with stage IA endometrial cancer and developed vaginal cuff recurrence 3 months after surgery.